Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Hydroxy-3-Methoxybenzene SCHEMBL28389126 | 0.82 | ESR1 (0.53) | CES2CES1PARP1MEN1KMT2A | |
| Trifluoromethanesulfonic Acid SCHEMBL3524850 | 0.82 | NPC1 (0.51) | CES2CES1PARP1RORARORC | |
| SCHEMBL29349442 | 0.80 | — | — | |
| SCHEMBL133589 | 0.80 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL18306126 | 0.80 | APP (0.44) | CES2CES1APPHSD11B1PRSS1 | |
| Trifluoromethanesulfonic Acid SCHEMBL1859837 | 0.80 | APP (0.44) | CES2CES1APPHSD11B1PRSS1 | |
| 1-Hydroxy-3-Methoxybenzene SCHEMBL7085846 | 0.79 | CES2 (0.41) | CES2CES1PARP1STSRORA | |
| Anisole SCHEMBL4551224 | 0.79 | CA4 (0.56) | CES2CES1KMT2AHSD11B1 | |
| Bromide SCHEMBL3349496 | 0.78 | ACHE (0.54) | CES2CES1PARP1MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL6118665 | 0.78 | ACHE (0.54) | CES2CES1PARP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741392-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | Seoul National University R & DB Foundation (KR) | 2020-11-25 | — | — | EP | claimed |
| CN-111954543-A | Positron emission tomography radioactive tracer for translocator overexpression related diseases, translocator targeting ligand for fluorescence imaging diagnosis and photodynamic therapy and preparation method thereof | 首尔国立大学校产学协力财团 | 2020-11-17 | — | — | CN | claimed |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2020-11-05 | — | — | US | claimed |
| WO-2019143016-A9 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2020-08-20 | — | — | WO | claimed |
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATGON (KR) | 2026-03-05 | — | — | US | disclosed |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-09 | — | — | US | disclosed |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-05-16 | — | — | US | disclosed |
| EP-3741392-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | Seoul National University R & DB Foundation (KR) | 2020-11-25 | — | — | EP | disclosed |
| CN-111954543-A | Positron emission tomography radioactive tracer for translocator overexpression related diseases, translocator targeting ligand for fluorescence imaging diagnosis and photodynamic therapy and preparation method thereof | 首尔国立大学校产学协力财团 | 2020-11-17 | — | — | CN | disclosed |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2020-11-05 | — | — | US | disclosed |
| WO-2019143016-A9 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING DIAGNOSIS AND PHOTODYNAMIC THERAPY, AND PREPARATION METHOD THEREFOR | 서울대학교산학협력단 | 2020-08-20 | — | — | WO | disclosed |
| WO-2010066357-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | CES2 3053/4885CES1 3279/4885PARP1 3567/4885 |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | TSPO, FABP7, SLC46A1 | CES2 3940/4885CES1 3179/4885PARP1 3860/4885 |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | CES2 3940/4885CES1 3179/4885PARP1 3860/4885 |
| US-20200345870-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, TMEM14C, FABP7 | CES2 3241/4885CES1 2496/4885PARP1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.